Rigel Pharmaceuticals (RIGL) Receivables - Other (2025 - 2026)
Rigel Pharmaceuticals' (RIGL) quarterly Receivables - Other came in at $1.0 million in Q1 2026, up 1654.39% year-on-year from $57000.0 in Q1 2025, and up 11.11% quarter-over-quarter from $900000.0 in Q4 2025.
Rigel Pharmaceuticals (RIGL) Receivables - Other (2025 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Receivables - Other history runs 2 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- On a quarterly basis, Receivables - Other rose 1654.39% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was $1.0 million, a 1654.39% increase from a year earlier, with the FY2025 full-year figure at $900000.0, changed N/A from the prior year.
- Receivables - Other advanced to $1.0 million in Q1 2026 per RIGL's latest filing, from $900000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $1.0 million in Q1 2026 and bottomed at $57000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Rigel Pharmaceuticals | 674.25 Mn | 527.57 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.00 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 900,000.00 |
| Dec 31, 2025 | 900,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Mar 31, 2025 | 57,000.00 |